Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC
Adding local consolidative therapy (LCT) after induction treatment with nivolumab plus ipilimumab did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC), including those with oligometastatic disease, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
